Affymetrix Q3 Revenues Rise 1 Percent on 'Strong Growth' in Genetic Analysis Business | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Wednesday that its third quarter revenues rose 1 percent year over year.

Total revenues for the three months ended Sept. 30 were $80.4 million, compared to $79.6 million in the same period last year. The results beat the average Wall Street estimate of $79 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.